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INTRODUCTION
Parkinson’s disease dementia (PDD) is
characterized by progressive cognitive
decline, mainly affecting executive func-
tions, which occurs in PD patients at least
1 year after the onset of motor symptoms,
when no other causes of dementia can be
detected. Such temporal cut-off allows to
discriminate between PDD and Lewy body
disease (LBD) in which dementia is present
since the disease onset, along with parkin-
sonism, visual hallucinations, and fluctu-
ations in the level of consciousness. The
prevalence of dementia in patients with PD
is 25%, increasing up to 80% in patients
with late onset after 20 years of follow-up.
In contrast, PDD has been detected in only
20% of young onset PD patients after a
follow-up of more than 18 years (1).
Clinical criteria for probable PDD
require a diagnosis of PD (2) and a slowly
progressive dementia syndrome. Typical
cognitive deficits in two of four domains
(attention, executive function, visuospa-
tial function, and free recall) and at least
one behavioral symptom (apathy, depres-
sion/anxious mood, hallucinations, delu-
sions, or excessive daytime sleepiness)
must be present. Exclusion criteria include
unknown time interval between motor
and cognitive symptoms, acute confusion,
resulting from systemic diseases or drug
intoxication and features compatible with
vascular dementia (3).
In recent years, several studies have
focused on predictive markers of cogni-
tive decline in PD. Clinical, neuroimaging,
and molecular markers have been identi-
fied. Nonetheless, which markers are most
reliable and applicable to clinical practice
to predict the long-term prognosis of these
patients still needs to be clarified.
POTENTIAL DISEASE MARKERS
Higher age at onset and gait impair-
ment are the best clinical predictors of
PDD. Community-studies showed that gait
impairment both precedes and predicts
dementia. Moreover, a direct correlation
between brain atrophy and freezing of gait
has been detected (4).
Neuroimaging studies have demon-
strated that PDD is associated with exten-
sive cortical atrophy, which may be quan-
tified with structural MRI. More detailed
imaging studies can differentiate PD
patients with mild cognitive impairment
(PD-MCI) from PDD. Voxel based mor-
phometry (VBM) shows that PD-MCI
patients display selective posterior corti-
cal atrophy, while PDD patients have a
more widespread cortical atrophy involv-
ing the posterior and temporal lobes, hip-
pocampus, and frontal association areas
(5). 18FDG PET in PDD patients shows
a pattern of hypometabolism targeting
parietal, occipital, temporal, frontal lobes,
and anterior cingulate cortex, which is
directly proportional to disease severity
(6). DaTSCAN SPECT shows that loss of
mesolimbic and mesocortical dopaminer-
gic function is likely to be more relevant to
PDD than DLB (7).
The cerebrospinal fluid (CSF) provides
relevant information on the central ner-
vous system (CNS) biochemical environ-
ment (8), and its study in neurodegen-
erative conditions has boosted since the
discovery of changes in beta amyloid/tau
concentrations in the CSF of Alzheimer’s
disease (AD) patients (9). Increased CSF
tau protein levels are typical of AD, but
they are also observed in other neurode-
generative diseases with rapid neuronal cell
loss, even independently from tau-related
pathology (10). Therefore, CSF tau should
be considered a non-specific marker of
neuronal degeneration (11). CSF tau lev-
els do not differ in PD patients and con-
trols, whereas PDD patients display higher
levels compared to PD patients but lower
than LBD and AD patients. On the con-
trary, CSF levels of phosphorylated tau are
not useful to differentiate these conditions
(12). α-synuclein, the major constituent of
Lewy bodies, was found to be decreased in
the CSF of PD patients at diagnosis com-
pared to controls. Such decrease was par-
ticularly evident in patients with akinetic-
rigid PD. On the contrary, no correlation
betweenα-synuclein levels and disease pro-
gression was found and no specific com-
parison between PD and PDD patients was
performed (13). Aβ-peptides are the major
constituents of amyloid plaques. Decreased
CSF levels of Aβ1–42 in PDD patients were
strongly associated with cognitive decline
over time, in particular, with a faster decline
in cognitive performances assessed by the
dementia rating scale (DRS) (14). Osteo-
pontin (OPN), a pro-inflammatory mole-
cule previously found to be associated with
AD progression (15), has also been stud-
ied in PD and LBD (16). OPN serum and
CSF levels are higher in PD patients than
controls, with CSF levels positively cor-
relating with concomitant dementia (17).
Accordingly, similar findings were reported
in LBD, where a single nucleotide poly-
morphism (SNP) of the OPN gene was
also shown to be associated to disease
susceptibility (18).
With regard to studies on serum and
plasma, just a few significant associations
between levels of circulating molecules and
PDD have been detected so far. In a study
assessing baseline plasma levels of 102
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proteins in PD patients, only decrease of
epidermal growth factor (EGF) was found
to correlate to poor cognitive scores at base-
line and predict a major risk of cognitive
decline (19). More recent studies have also
suggested association between serum levels
of uric acid (20) and plasma homocysteine
(21) and the development of dementia,
but such results need replication in larger
cohorts.
The potential markers for PDD devel-
opment that we have reviewed so far have,
however, some downsides: neuroimaging
studies are generally not invasive but they
are very expensive and require advanced
technology, highly specialized operators
and patients’ collaboration for a long
period of time.
Studies on body fluids are generally less
expensive than imaging, but in case of
CSF studies, they require an invasive pro-
cedure, with potential risks, especially in
the elderly. Furthermore, circulating mole-
cules can serve as prognostic markers only
if the sample is obtained at the time of diag-
nosis, when patients are drug-naive and
the disease is in its early phase. In fact,
biological molecules may undergo bio-
chemical changes during the evolution of
the disease and due to pharmacological
treatment (22).
In recent years, proteomic techniques
have been increasingly used to explore the
molecular mechanisms underlying PD and
to detect biomarkers allowing early diagno-
sis, prediction of disease progression, and a
more targeted treatment. Proteomics can
be performed on CSF, plasma, or circu-
lating cells (23). Nonetheless, it is gener-
ally quite expensive and no definite bio-
marker has entered the routine clinical
practice so far.
ROLE OF GENETICS
Genetic studies may provide ideal markers
for predicting disease progression as DNA
sequence is not likely to undergo changes
during disease course and is not influenced
by drug treatment. Preliminary prognostic
correlations can be obtained with cross-
sectional or even retrospective data. To
this respect, the genetic background of
PDD has been explored with both unbiased
and candidate–gene approaches. Although
most genome wide association studies
(GWAS) performed so far were focused on
PD susceptibility, Chung et al. analyzed the
common variants associated with motor
and cognitive progression in 443 PD sub-
jects. Two potential markers of progres-
sion were identified: SNP rs6482992 of
CLRN3 and SNP rs10958605 of C8orf4:
the former provided the best prediction of
cognitive deterioration [hazard ratio 1.81,
p= 1.81× 10(−6)], the latter, which is
likely involved in neuroinflammatory path-
ways (8), was associated with both motor
and cognitive outcomes.
Traditional candidate–gene approaches
have mainly focused on genes involved
in pathways of neurodegeneration, such
as mitochondrial transcription fac-
tor A (TFAM) or brain derived neu-
rotrophic factor (BDNF); alternatively,
genes like apolipoprotein E (APOE)
and microtubule-associated protein Tau
(MAPT), were selected among those
previously associated with AD (24).
A SNP in the gene encoding TFAM,
A>G rs2306604, has been recently stud-
ied in PDD patients compared to controls.
Data showed that the A allele was associated
with PDD (p= 0.024, OR= 2.092), even
though such findings need to be replicated
in a larger population (25).
Brain derived neurotrophic factor is a
trophic factor that can act as synaptic
modulator and interact with dopaminer-
gic transmission and dopamine receptor
stimulation in the fronto-striatal circuitry,
whose integrity is crucial for the cognitive
aspects of PD. A SNP in the BDNF gene,
namely, G196A, resulting in a methionine
(Met)–valine (Val) substitution at codon
66 (Val66Met), was shown to be associ-
ated with increased susceptibility to AD
(26). Intriguingly, PD patients carrying AA
genotype of G196A display significantly
increased risk of cognitive decline (27).
The ε4 allele of APOE was shown to
be associated with higher prevalence of
dementia in PD patients. A meta-analysis
indicated an over-representation of APOE
ε4 carriers in PDD patients compared to
non-demented cases [OR 1.74 (1.36–2.23)]
(28). To further support these findings, two
recent reports confirmed that APOE ε4 is
an important predictor of cognitive func-
tion in PD across multiple domains (i.e.,
recall and delayed recall, semantic verbal
fluency) (29) and it also has a relevant
influence on the memory domain (30).
The H1/H1 haplotype of MAPT was
associated with an increased risk of several
neurodegenerative disorders. A possible
association between the H1 allele and cog-
nitive decline in PD was explored, but
the results obtained were conflicting, with
some studies showing a positive correla-
tion between PDD and the H1 allele, in
particular, with the sub-haplotype H1p
(31), and others that provided negative
results (32).
Important insights into the relationship
between genetics and the cognitive progres-
sion of PD derive from the natural history
of familial cases. PARKIN and leucine-rich
repeat kinase 2 (LRRK2) mutations are
associated to a lower rate of PDD com-
pared to sporadic cases, whereas oppo-
site findings were shown for α-synuclein
(SNCA) or glucocerebrosidase (GBA) gene
mutations.
The risk of dementia in patients with
PARKIN mutations is reported to be very
low (33). Nonetheless, neuropsychiatric
features are reported, including anxiety,
psychosis, panic attacks, depression, dis-
turbed sexual behavioral, and obsessive–
compulsive disorders. A recent cross-
sectional study, comparing outcome in 21
PARKIN mutation carriers versus 23 idio-
pathic PD (IPD) patients, showed that
PARKIN carriers had better performance,
not only on the motor score but also
on attention, memory, and visuospatial
cognitive domains compared with non-
carriers.
Leucine-rich repeat kinase 2 is a com-
mon genetic cause of PD and Gly2019Ser is
the most frequent mutation. It was shown
that Gly2019Ser carriers have lower PPD
risk compared to IPD patients, particularly
in the first 2 years of disease (34).
SNCA gene point mutations (A53T,
A30P, and E46K), named PARK1, as well
as duplications and triplications (PARK4),
cause autosomal dominant PD with vari-
able penetrance. Clinically, carriers may
have rapid motor progression and fre-
quent dementia, in particular, triplications
result in earlier onset of PD and demen-
tia (35). Moreover, functional SNCA SNPs
are associated with different rates of motor
progression in IPD (36).
Heterozygous GBA mutations are over-
represented in cases of both familial
and sporadic PD. Compared with IPD,
patients carrying GBA mutations have
been reported to have an earlier age at
onset, more symmetrical clinical signs, and
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an increased incidence of neuropsychi-
atric disturbances (37). In 2012, Winder-
Rhodes et al. demonstrated that in PD
patients with single GBA mutations the
risk of progression to dementia is more
than five times higher that the one of
GBA-negative patients, but the mechanism
underlying this association has yet to be
elucidated (38).
With the progress in genotyping and
sequencing technologies, discovery of
novel genetic markers associated with dis-
ease onset, progression, and response to
treatment is expected. Nonetheless, the use
of genetic markers to predict disease pro-
gression and specifically cognitive impair-
ment in PD patients requires a great effort
in collecting accurate and reproducible
clinical data. To standardize procedures for
acquisition, processing, and storage of clin-
ical data which are often not homogeneous,
is mandatory to improve the quality of the
research. It is conceivable to collect more
accurate indicators of dementia, through
the systematic use of specific rating scales
(e.g., DRS) that also take into account the
interference of cognitive decline with the
activities of daily living. This would even-
tually help in early identifying a subgroup
of PD patients at risk of dementia to be
enrolled in clinical trials of novel and more
specific treatments. Finally, large collabo-
rative studies involving several institutions
will be required to prospectively validate
the utility of these markers for clinical
decision making.
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